Clinical trials: HPV InfectioN
Common Warts
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts
Nonclinical studies have shown sandalwood oil to have anti-inflammatory, anti-fungal, antiviral, and anti-bacterial activities. Previous clinical studies have shown East Indian Sandalwood oil to be promising as a treatment for…
- Trial name
- NCT01286441
- Testing
- 10% EISO, 20% EISO, 30% EISO
- Where
- 20 sites in United States
- Volunteers
- 183 people
- Sponsor
- ViroXis Corporation
Conscripts, Military Induction Board
Prevalence of ENT Diseseas
The aim of the present study will be to evaluate in conscripts at the military induction board the prevalence of rhinosinusitis, the prevalence of HPV vaccinations, the prevalence of hearing impairments and the prevalence of…
- Conditions
- Conscripts, Military Induction Board, ENT Disease, Rhinosinusitis Chronic
- Trial name
- PrENT (NCT06105346)
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Infections, Papillomavirus
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a…
- Trial name
- NCT00426361
- Testing
- Boostrix ® Polio, GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)
- Where
- 38 sites in France, Germany and 1 more
- Volunteers
- 751 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Verruca Viral
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
Common warts are papulonodular epidermal lesions caused by human papillomavirus (HPV) usually by the strains 1, 2, 4, 27 or 57. Cutaneous warts occur in 7% to 10% of the general population, with a maximum incidence between 12 and…
- Trial name
- MMR (NCT04428359)
- Testing
- Measles-Mumps-Rubella Vaccine, Vit D
- Where
- Nepal
- Volunteers
- 66 people
- Sponsor
- B.P. Koirala Institute of Health Sciences
Cervical Cancers, Papillomavirus Infections
Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)
The aim of this retrospective, single-center, observational study is to improve the diagnosis and interpretation of cervical cancer by better detection of epithelial lesions in the case of a late HPV PCR amplification signal…
- Conditions
- Cervical Cancers, Papillomavirus Infections, Papillomavirus Type 16/18 Infection
- Trial name
- PaPCR (NCT06919627)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Brest
Human Papillomavirus, CIN 2
Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women
The natural history of human papillomavirus (HPV) is most likely influenced by both innate and adaptive mucosal immunity. More specifically, we hypothesize that Toll like receptors (TLR) play an important role in cervical innate…
- Conditions
- Human Papillomavirus, CIN 2, CIN 3
- Trial name
- NCT01366742
- Where
- 2 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HPV Infection
Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+
This research is being done to test the safety and feasibility of an investigational DNA vaccine called pBI-11 and to find out what effects, if any, it has on women with persistent human papillomavirus 16 (HPV16+) and/or human…
- Trial name
- NCT06210854
- Testing
- pBI-11 (3 doses), pBI-11 (1 dose)
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Immunization, HPV Infection
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response.
- Conditions
- Immunization, HPV Infection, Human Papillomavirus
- Trial name
- NCT05672927
- Testing
- 9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
HPV-Related Cervical Carcinoma
HPV Immunological Markers of Cervical Persistent Infection and Oncogenesis
The aim of this observational study is to build an immunological assay to quantify an immunoscore system for clinical practice, which could identify HPV lesions with a risk of persistent cervical infection, which represents the…
- Trial name
- HPVImmuno (NCT06339684)
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults
This phase IV trial examines the impact of an education program on the human papilloma virus (HPV) and its effects on the acceptance and completion rates of a free HPV vaccination program in underserved adult patients.
- Trial name
- NCT04474821
- Testing
- Educational Intervention, Survey Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Cervical Intraepithelial Neoplasia, Cervical Cancer
The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
The primary objective of this study is to evaluate the durability of protection and immuno-persistence of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT05045755
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 1,339 people
- Sponsor
- Jun Zhang
HIV Infections, HPV Infection
HPV Infection and Vaginal Microecology in Immunosuppressed Women
This study intends to establish a screening cohort for HPV infection and related tumors in areas with high incidence of HIV infection, explore the screening of cervical cancer and anal cancer and the prognosis management model of…
- Conditions
- HIV Infections, HPV Infection, Cervical Cancer, Anal Cancer
- Trial name
- NCT06619743
- Volunteers
- 10,000 people
- Sponsor
- Lan Zhu
HIV Infections, Sexually Transmitted Diseases
Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community
This randomized controlled trial conducted in Rakai District, Uganda, has enrolled 997 HIV positive men and 500 men who declined to learn HIV results (regardless of HIV status).
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Papillomavirus Infections, Genital Herpes
- Trial name
- NCT00124878
- Testing
- Male circumcision
- Where
- Uganda
- Volunteers
- 5,200 people, healthy volunteers welcome
- Sponsor
- Wawer, Maria J., M.D.
Vaginal Flora Imbalance, ASC-US
"Lactobacillus Crispatus M247, LSIL and Microbiota"
Patients affected by ASC-US/ low-grade HPV cervical lesions will be randomly assigned to treatment arm vs control arm. The treatment arm will include the characterization of the vaginal microbiota at enrollment (T0), 4 months of…
- Conditions
- Vaginal Flora Imbalance, ASC-US, LSIL, HPV Infection
- Trial name
- NCT05808816
- Testing
- Lactobacillus Crispatus M247
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Infection by Human Papilloma Virus
Dynamics of Human PApilloma Virus Interactions; Internet-based Students HeAlth Research Enterprise
Human papillomavirus (HPV) infection is the most common sexually transmitted infection. The high risk oncogenic types, HPV-16 and -18 are responsible for 70% of cervical cancers.
- Trial name
- DyPAVIR (NCT01988948)
- Testing
- Various biological sampling
- Where
- France
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
HPV-induced Cancers, HPV Infections
Tolerance and Effectiveness of C14 on HPV Infection
The zinc monoterpenoid tetra-ascorbo-camphorate possesses broad-spectrum anti-viral properties in vitro, particularly against HIV, HSV and HPV.
- Conditions
- HPV-induced Cancers, HPV Infections, HIV, Cervical Cancers
- Trial name
- PREPAP (NCT06672653)
- Testing
- The monoterpenoid zinc tetra-ascorbo-camphorate ("C14"), Distilled water group
- Where
- Democratic Republic of the Congo
- Volunteers
- 66 people
- Sponsor
- MGB Pharma
HPV Infections
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
This study is designed to determine the tolerability and immunogenicity of a 3-dose regimen of Gardasil administered to healthy married females between 16 and 23 years of age, in India.
- Trial name
- NCT00733122
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasia, Cervical Cancer
The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
The primary objective of this study is to evaluate the durability of protection of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT04969445
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 647 people
- Sponsor
- Jun Zhang
Cervical Cancer, Condylomata Acuminata
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
This study is designed to compare the immunogenicity of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females…
- Trial name
- NCT04782895
- Testing
- Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9
- Where
- China
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Human Immunodeficiency Virus, HPV Infection
Thermocoagulation for Treatment of Precancerous Cervical Lesions
The purpose of this study is to evaluate the safety, acceptability, and efficacy of Thermocoagulation for treatment of precancerous lesions among HIV-positive women in a screen-and-treat program in Western Kenya.
- Conditions
- Human Immunodeficiency Virus, HPV Infection, CIN 2/3
- Trial name
- NCT04191967
- Testing
- Thermocoagulation
- Where
- Kenya
- Volunteers
- 379 people
- Sponsor
- University of California, San Francisco